SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-22-039976
Filing Date
2022-07-18
Accepted
2022-07-18 16:05:39
Documents
12
Period of Report
2022-07-16
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea162974-8k_protara.htm   iXBRL 8-K 45315
  Complete submission text file 0001213900-22-039976.txt   220268

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE tara-20220716.xsd EX-101.SCH 2962
3 XBRL LABEL FILE tara-20220716_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE tara-20220716_pre.xml EX-101.PRE 22361
6 EXTRACTED XBRL INSTANCE DOCUMENT ea162974-8k_protara_htm.xml XML 3629
Mailing Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010 646-844-0337
Protara Therapeutics, Inc. (Filer) CIK: 0001359931 (see all company filings)

IRS No.: 204580525 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36694 | Film No.: 221089250
SIC: 2836 Biological Products, (No Diagnostic Substances)